Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 880

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 880
---
:--|:--|:-----|:--|----------:|:--|:--|:--|:-----|:--|----------:|:--|:--|
| Net loss – basic and diluted                | ​ | ​ | ​                       | $ |  -118,513 | ​ | ​ | ​ | ​    | $ |   -85,474 | ​ | ​ | ​ | ​    | $ |   -88,441 | ​ | ​ |
| Weighted-average common shares outstanding: | ​ | ​ | ​                       | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ |
| Basic and diluted                           | ​ | ​ | ​                       | ​ | 4,512,422 | ​ | ​ | ​ | ​    | ​ | 4,471,130 | ​ | ​ | ​ | ​    | ​ | 4,226,564 | ​ | ​ |
| Net loss per share, basic and diluted:      | ​ | ​ | ​                       | $ |    -26.26 | ​ | ​ | ​ | ​    | $ |    -19.12 | ​ | ​ | ​ | ​    | $ |    -20.93 | ​ | ​ |

As of December 31, 2023, 658,138 stock options and 47,194 restricted stock units were outstanding, which could potentially dilute basic earnings per share in the future, but were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive as a result of the net loss for the period. As of December 31, 2022, 640,787 stock options and 31,043 restricted stock units were outstanding, which could potentially dilute basic earnings per share in the future, but were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive as a result of the net loss for the period. As of December 31, 2021, 542,690 stock options and 48,045 restricted stock units were outstanding, which could potentially dilute basic earnings per share in the future, but were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive as a result of the net loss for the period.

F-